Current state of total artificial heart therapy and introduction of the most important total artificial heart systems

2019 ◽  
Vol 64 (3) ◽  
pp. 247-250
Author(s):  
Sotirios Spiliopoulos ◽  
Vera Hergesell ◽  
Andrae Wasler ◽  
Otto Dapunt
Keyword(s):  
Heart Failure ◽  
Organ Donation ◽  
Clinical Outcomes ◽  
Artificial Heart ◽  
Cardiac Transplantation ◽  
Total Artificial Heart ◽  
Successful Implementation ◽  
Technical Requirements ◽  
Current State ◽  
End Stage

AbstractDue to the declining instances of organ donation, total artificial heart (TAH) therapy is of increasing importance for the management of end-stage biventricular heart failure. We introduce the currently most important established and novel TAH systems (SynCardia, CARMAT, ReinHeart, BiVACOR), report clinical outcomes and discuss technical requirements for the successful implementation of TAH therapy as an alternative to cardiac transplantation.

The Biocompatibility Challenges in the Total Artificial Heart Evolution

2019 ◽  
Vol 21 (1) ◽  
pp. 85-110 ◽  
Author(s):  
Eleonora Dal Sasso ◽  
Andrea Bagno ◽  
Silvia T.G. Scuri ◽  
Gino Gerosa ◽  
Laura Iop
Keyword(s):  
Heart Failure ◽  
Artificial Heart ◽  
Comprehensive Analysis ◽  
Therapeutic Options ◽  
Total Artificial Heart ◽  
Final Treatment ◽  
End Stage Heart Failure ◽  
End Stage

There are limited therapeutic options for final treatment of end-stage heart failure. Among them, implantation of a total artificial heart (TAH) is an acceptable strategy when suitable donors are not available. TAH development began in the 1930s, followed by a dramatic evolution of the actuation mechanisms operating the mechanical pumps. Nevertheless, the performance of TAHs has not yet been optimized, mainly because of the low biocompatibility of the blood-contacting surfaces. Low hemocompatibility, calcification, and sensitivity to infections seriously affect the success of TAHs. These unsolved issues have led to the withdrawal of many prototypes during preclinical phases of testing. This review offers a comprehensive analysis of the pathophysiological events that may occur in the materials that compose TAHs developed to date. In addition, this review illustrates bioengineering strategies to prevent these events and describes the most significant steps toward the achievement of a fully biocompatible TAH.

scholarly journals Paving the way for destination therapy of end-stage biventricular heart failure: the ReinHeart total artificial heart concept

2014 ◽  
Vol 46 (6) ◽  
pp. 935-936 ◽  
Author(s):  
R. Koerfer ◽  
S. Spiliopoulos ◽  
T. Finocchiaro ◽  
D. Guersoy ◽  
G. Tenderich ◽  
...  
Keyword(s):  
Heart Failure ◽  
Artificial Heart ◽  
Total Artificial Heart ◽  
Destination Therapy ◽  
End Stage ◽  
The Way

Effect of a Total Artificial Heart on Adaptive Hormonal Responses in Humans with End-Stage Heart Failure

1989 ◽  
Vol 35 (3) ◽  
pp. 229-230 ◽  
Author(s):  
KEVIN D. MURRAY ◽  
P. DAVID MYEROWITZ ◽  
KIM M. WATSON ◽  
PATTY A. LOWE ◽  
LAURI K. KALANGES ◽  
...  
Keyword(s):  
Heart Failure ◽  
Artificial Heart ◽  
Total Artificial Heart ◽  
Hormonal Responses ◽  
End Stage Heart Failure ◽  
End Stage

Effect of a Total Artificial Heart on Adaptive Hormonal Responses in Humans with End-Stage Heart Failure

1989 ◽  
Vol 35 (3) ◽  
pp. 229-230
Author(s):  
KEVIN D. MURRAY ◽  
P. DAVID MYEROWITZ ◽  
KIM M. WATSON ◽  
PATTY A. LOWE ◽  
LAURI K. KALANGES ◽  
...  
Keyword(s):  
Heart Failure ◽  
Artificial Heart ◽  
Total Artificial Heart ◽  
Hormonal Responses ◽  
End Stage Heart Failure ◽  
End Stage

scholarly journals The Use of Total Artificial Heart With Example of Cases for End-Stage Heart Failure Therapy

2013 ◽  
Vol 62 (18) ◽  
pp. C45
Author(s):  
Serkan Ertugay ◽  
Özlem Balcıoğlu ◽  
Ayşen Yaprak Engin ◽  
Emrah Oğuz ◽  
Çağatay Engin ◽  
...  
Keyword(s):  
Heart Failure ◽  
Artificial Heart ◽  
Total Artificial Heart ◽  
Heart Failure Therapy ◽  
End Stage Heart Failure ◽  
End Stage

scholarly journals A bioprosthetic total artificial heart for end-stage heart failure: Results from a pilot study

2018 ◽  
Vol 37 (1) ◽  
pp. 33-37 ◽  
Author(s):  
Christian Latrémouille ◽  
Alain Carpentier ◽  
Pascal Leprince ◽  
Jean-Christian Roussel ◽  
Bernard Cholley ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pilot Study ◽  
Artificial Heart ◽  
Total Artificial Heart ◽  
End Stage Heart Failure ◽  
End Stage

scholarly journals The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin

2017 ◽  
Vol 39 (20) ◽  
pp. 1794-1798 ◽  
Author(s):  
Mattia Arrigo ◽  
Nicolas Vodovar ◽  
Hélène Nougué ◽  
Malha Sadoune ◽  
Chris J Pemberton ◽  
...  
Keyword(s):  
Heart Failure ◽  
Coronary Sinus ◽  
Artificial Heart ◽  
Systolic Function ◽  
Systolic Dysfunction ◽  
Venous Blood ◽  
Left Ventricular Systolic Function ◽  
Left Ventricular ◽  
Total Artificial Heart ◽  
Endocrine Response

Abstract Aims Heart failure (HF) is accompanied by major neuroendocrine changes including the activation of the natriuretic peptide (NP) pathway. Using the unique model of patients undergoing implantation of the CARMAT total artificial heart and investigating regional differences in soluble neprilysin (sNEP) in patients with reduced or preserved systolic function, we studied the regulation of the NP pathway in HF. Methods and results Venous blood samples from two patients undergoing replacement of the failing ventricles with a total artificial heart were collected before implantation and weekly thereafter until post-operative week 6. The ventricular removal was associated with an immediate drop in circulating NPs, a nearly total disappearance of circulating glycosylated proBNP and furin activity and a marked decrease in sNEP. From post-operative week 1 onwards, NP concentrations remained overall unchanged. In contrast, partial recoveries in glycosylated proBNP, furin activity, and sNEP were observed. Furthermore, while in patients with preserved systolic function (n = 6), sNEP concentrations in the coronary sinus and systemic vessels were similar (all P > 0.05), in patients with reduced left-ventricular systolic function, sNEP concentration, and activity were ∼three-fold higher in coronary sinus compared to systemic vessels (n = 21, all P < 0.0001), while the trans-pulmonary gradient was neutral (n = 5, P = 1.0). Conclusion The heart plays a pivotal role as a regulator of the endocrine response in systolic dysfunction, not only by directly releasing NPs but also by contributing to circulating sNEP, which in turn determines the bioavailability of other numerous vasoactive peptides.

Sign in / Sign up

Export Citation Format

Share Document